An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Latest Information Update: 30 Jun 2023
At a glance
- Drugs Delanzomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 10 May 2023 The given protocol has been amended as-1)Number of treatment arms has been changed from 1 to 3.2)Status of the trial has been changed from terminated to completed.3) The sponsor of the study is Teva Branded Pharmaceutical Products R&D.4) Sequential Assignment has been included.
- 10 May 2023 Status changed from discontinued to completed.
- 31 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.